Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 355

1.

Projected Uptake of New Antiretroviral (ARV) Medicines in Adults in Low- and Middle-Income Countries: A Forecast Analysis 2015-2025.

Gupta A, Juneja S, Vitoria M, Habiyambere V, Nguimfack BD, Doherty M, Low-Beer D.

PLoS One. 2016 Oct 13;11(10):e0164619. doi: 10.1371/journal.pone.0164619. eCollection 2016.

2.
3.

An in vitro evaluation of drugs used in the Kenyan ART program.

Muriuki J, Ng'ang'a Z, Lihana R, Lwembe R, Mwangi J, Mwau M.

Pan Afr Med J. 2016 Mar 25;23:134. doi: 10.11604/pamj.2016.23.134.7157. eCollection 2016.

4.

[Declining costs].

Neumaier J.

MMW Fortschr Med. 2016 Jun 9;158 Suppl 1:58. doi: 10.1007/s15006-016-8330-x. German. No abstract available.

PMID:
27259908
5.

TRIPS AGREEMENT ARTICLE 31(B): THE NEED FOR REVISION.

Effingham AM.

Seton Hall Law Rev. 2016;46(3):883-909. No abstract available.

PMID:
27066613
6.

An analysis of volumes, prices and pricing trends of the pediatric antiretroviral market in developing countries from 2004 to 2012.

Lee JS, Sagaon Teyssier L, Dongmo Nguimfack B, Collins IJ, Lallemant M, Perriens J, Moatti JP.

BMC Pediatr. 2016 Mar 15;16:41. doi: 10.1186/s12887-016-0578-x.

7.

Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.

Yi HA, Fochtman BC, Rizzo RC, Jacobs A.

Curr HIV Res. 2016;14(3):283-94. Review.

8.

Generic antiretroviral drugs and HIV care: An economic review.

Yazdanpanah Y, Schwarzinger M.

Med Mal Infect. 2016 Mar;46(2):67-71. doi: 10.1016/j.medmal.2016.01.003. Epub 2016 Feb 19. Review.

PMID:
26905394
9.

Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US.

Pei PP, Weinstein MC, Li XC, Hughes MD, Paltiel AD, Hou T, Parker RA, Gaynes MR, Sax PE, Freedberg KA, Schackman BR, Walensky RP.

HIV Clin Trials. 2015 Nov;16(6):207-18. doi: 10.1080/15284336.2015.1123942. Epub 2015 Dec 11.

10.

Optimizing drugs to reach treatment targets for children and adolescents living with HIV.

Penazzato M, Lee J, Capparelli E, Essajee S, Ford N, Ojoo A, Pascual F, Sugandhi N, Lallemant M.

J Int AIDS Soc. 2015 Dec 2;18(Suppl 6):20270. doi: 10.7448/IAS.18.7.20270. eCollection 2015. Review.

11.
12.

Compulsory licensing often did not produce lower prices for antiretrovirals compared to international procurement.

Beall RF, Kuhn R, Attaran A.

Health Aff (Millwood). 2015 Mar;34(3):493-501. doi: 10.1377/hlthaff.2014.0658.

PMID:
25732501
13.

Correlation between microstructure and bioequivalence in anti-HIV drug efavirenz.

Fandaruff C, Segatto Silva MA, Galindo Bedor DC, de Santana DP, Rocha HV, Rebuffi L, Azanza Ricardo CL, Scardi P, Cuffini SL.

Eur J Pharm Biopharm. 2015 Apr;91:52-8. doi: 10.1016/j.ejpb.2015.01.020. Epub 2015 Feb 3.

PMID:
25661587
14.

Perception of antiretroviral generic medicines: one-day survey of HIV-infected patients and their physicians in France.

Jacomet C, Allavena C, Peyrol F, Pereira B, Joubert LM, Bagheri H, Cotte L, Garaffo R, Gerbaud L, Dellamonica P.

PLoS One. 2015 Feb 6;10(2):e0117214. doi: 10.1371/journal.pone.0117214. eCollection 2015.

15.

Strategies to reduce risks in ARV supply chains in the developing world.

Larson C, Burn R, Minnick-Sakal A, Douglas MO, Kuritsky J.

Glob Health Sci Pract. 2014 Dec 10;2(4):395-402. doi: 10.9745/GHSP-D-14-00105. No abstract available.

16.
17.

Quality of antiretroviral and opportunistic infection medications dispensed from developing countries and Internet pharmacies.

Wang T, Hoag SW, Eng ML, Polli J, Pandit NS.

J Clin Pharm Ther. 2015 Feb;40(1):68-75. doi: 10.1111/jcpt.12226. Epub 2014 Nov 10.

PMID:
25381836
18.

Production of antiretroviral drugs in middle- and low-income countries.

Pinheiro Edos S, Brüning K, Macedo MF, Siani AC.

Antivir Ther. 2014;19 Suppl 3:49-55. doi: 10.3851/IMP2900. Epub 2014 Oct 13. Review.

PMID:
25310755
19.

Prices paid for adult and paediatric antiretroviral treatment by low- and middle-income countries in 2012: high, low or just right?

Perriëns JH, Habiyambere V, Dongmo-Nguimfack B, Hirnschall G.

Antivir Ther. 2014;19 Suppl 3:39-47. doi: 10.3851/IMP2899. Epub 2014 Oct 13. Review.

PMID:
25310645
20.

Simplification of antiretroviral therapy: a necessary step in the public health response to HIV/AIDS in resource-limited settings.

Vitoria M, Ford N, Doherty M, Flexner C.

Antivir Ther. 2014;19 Suppl 3:31-7. doi: 10.3851/IMP2898. Epub 2014 Oct 13. Review.

PMID:
25310534

Supplemental Content

Loading ...
Support Center